Donor lymphocyte infusions (DLIs) after allo-SCT displayed limited use in CLL and highly malignant nonHodgkin's lymphoma (NHL). Here we studied whether Bi20 (FBTA05), a novel trifunctional bispecific antibody targeting CD20 on lymphoma cells and CD3 on T cells, could induce GVL responses in combination with DLI or mobilized PBSCT after allogeneic transplantation in these diseases. Six patients (three cases with p53-mutated CLL and three with high-grade NHL (HG-NHL)) refractory to standard therapy were treated with escalating doses of Bi20 (range 10-2000 lg) followed by DLI or SCT. Thereby, all CLL patients showed a prompt but transient clinical and hematological response. In one patient with HG-NHL, we observed a halt in progression for almost 4 months. Side effects (fever, chills and bone pain) were tolerable and appeared at antibody dose levels between 40 and 200 lg. The cytokine profile was characterized by transient increases of IL-6, IL-8 and IL-10. Neither human anti-mouse antibodies nor GVHD developed, allowing repeated treatment courses. In summary, the trifunctional antibody Bi20 induced prompt antitumor responses in extensively pretreated, p53-mutated alemtuzumab and rituximab refractory patients indicating its therapeutic potential.
Introduction
Evidence for a GVL effect of allo-SCT in highly malignant lymphoma is limited 1 and has been discussed controversially. [2] [3] [4] In a retrospective data analysis of the International Bone Marrow Transplant Registry and European Group for Blood and Marrow Transplantation, allogeneic transplantation was not superior to syngeneic transplantation, indicating the absence of an allogeneic GVL effect. 5 However, several studies and observations report a GVL effect of donor lymphocyte infusions (DLIs). [6] [7] [8] [9] Furthermore, cells of highly malignant lymphoma may escape recognition and destruction by allogeneic lymphocytes by various mechanisms. Downregulation of HLA antigens and costimulatory molecules as well as secretion of inhibitory cytokines such as transforming growth factor-b might be involved and disturb the generation of alloreactive T-cell immunity. Antibodies are, at least at first glance, unaffected by these mechanisms and have been used with increasing success in the treatment of patients with indolent and aggressive lymphoma as well as CLL. Rituximab (MabThera, Rituxan) is an IgG1 chimeric monoclonal antibody directed against the CD20 antigen that improved response and survival of patients. The mechanism of activity is not entirely clear; antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity and induction of apoptosis have been shown. 10 The delayed therapeutic effect has been discussed as evidence for potential vaccination effect. 10 In that context, bispecific antibodies might be a highly attractive therapeutic concept directing T cells efficiently toward tumor cells. 11, 12 Moreover, bispecific antibodies carrying a functional Fc part provide the additional capacity to recruit Fcg receptor-bearing accessory cells such as macrophages, DCs and natural killer cells. In this way, an optimal vaccination might be achieved by inducing T-cell cytotoxicity, phagocytosis and processing of relevant antigenic peptides, resulting in a lasting cellular immunity. 13 Here we report on the use of Bi20 (FBTA05), a trifunctional heterodimeric anti-CD3 (rat IgG2b) Â anti-CD20 (mouse IgG2a) antibody, already shown to kill lymphoma cells very effectively even at very low expression levels in vitro. 14 In a pilot study, we treated six patients with recurrent B-cell malignancies, CLL and highly malignant lymphoma after allo-SCT. Escalating doses of Bi20 were followed by DLI or mobilized PBSCT. Here we show that Bi20 could induce a prompt tumor response in some patients with advanced disease, whereas the toxicity of treatment was tolerable.
Patients and methods

Patients
In a pilot trial, six patients with recurrent and refractory B-cell malignancies after allo-SCT were treated with escalating doses of Bi20 (anti-CD3 Â anti-CD20) followed by DLI or mobilized PBSCT. Three patients (nos. 1, 2 and 3) had been treated for refractory CLL with SCT from HLA-identical sibling donors, and patient nos. 4, 5 and 6 had been treated for refractory high-grade lymphoma with SCT from HLA-haploidentical family donors. The internal review board and ethics committee were informed about the individual treatment plans. Informed consent of the patient was provided according to the Declaration of Helsinki.
The patient characteristics and earlier treatments are summarized in Table 1 . In all patients, chimerism was proved by the demonstration of sex chromosomes of the donor in blood and/or marrow, HLA typing and/or short tandem repeats; signs and symptoms of GVHD and infections were absent. Patient nos. 1, 2 and 3 had recurrent B-CLL with p53 mutations. Patient no. 1 had already undergone re-transplantation and three treatments with DLI. Patient nos. 4, 5 and 6 presented with recurrent highgrade lymphoma. The histology of patient no. 4 was Burkitt-like lymphoma and those of patient nos. 5 and 6 were diffuse large B-cell lymphoma (DLBCL). The highgrade lymphoma patients had received HLA-haploidentical transplantation after chemotherapy; radiation therapy or antibody (rituximab) treatment had failed.
Expression of CD20 was confirmed by immunohistochemistry or flow cytometric analysis, and anti-CD20 treatment was not given 3 months before start of the treatment with Bi20. Testing for human anti-mouse antibodies (HAMAs) was negative in all patients. The decision for treatment was taken as other treatment options were not available.
Treatment schedule
All patients were treated with escalating doses of Bi20 (anti-CD3 Â anti-CD20) followed by DLI or PBSCT of their allogeneic stem cell donor (Table 2 ). Patient no. 1 with advanced CLL received a test dose of 10 mg Bi20 on day 1, which was doubled every second day and increased up to 600 mg on day 17, followed by DLI (1 Â 10 7 CD3 þ cells per kg of recipient body weight) on day 18. In patient no. 2 (CLL), Bi20 was escalated up to 1000 mg followed on day 28 by DLI (1 Â 10 6 CD3 þ cells per kg of recipient body weight). DLI was further escalated up to 1 Â 10 7 CD3
þ Staging of CLL according to Binet classification; staging of B-cell lymphoma according to Ann Arber classification.
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The treatment was considered as an individual trial in an otherwise hopeless situation based on promising in vitro data. It allowed the investigation of safety and tolerability of Bi20 (anti-CD3 Â anti-CD20) in combination with DLI as well as antitumor activity and monitoring of different immunologic variables (hematological cell populations, cytokine release and HAMAs).
Drug formulation and administration
Bi20 was supplied by TRION Research (Munich, Germany) as a sterile, pyrogen-free, color-free and preservative-free solution for infusion. The concentrate contained 0.2 mg/ml antibody per 100 mM sodium citrate buffer (pH 5.6), with 0.02% Tween 80. Depending on the dose level, Bi20 was further diluted in 0.9% sodium chloride solution for i.v. infusion. The antibody was administered as a continuous 6-12 h i.v. infusion by a precision infusion pump. Paracetamol (1000 mg orally) and antihistamines (for example, clemastine, 2 mg i.v.) were given as premedication 30 min before antibody infusion. To avoid blood pressure instability and hypotension, 1000 ml of Ringer's solution was given 15 min before treatment. Intensive care monitoring was performed up to 24 h after the start of infusion.
Toxicity and safety evaluation Toxicity and adverse events were assessed by clinical examination and laboratory tests, classified by their relationship with study treatment and graded according to the National Cancer Institute (NCI) Common Toxicity Criteria (CTC).
Clinical and experimental response evaluation
Patients were in the hospital when the decision for treatment was taken. Baseline complete blood count, serum chemistries, electrocardiogram as well as appropriate radiological scans for tumor assessment were obtained from each patient. Hematological and immunological parameters (for example, blood counts, serum chemistry, cytokine levels for IL-6, tumor necrosis factor-a and lymphocyte subsets) were assessed before and 24 h after each Bi20 infusion, respectively, DLI or SCT. Disease evaluation was performed according to the corresponding working group guidelines for CLL and NHL. 15, 16 In this study, clinical and laboratory evaluations were followed up weekly after treatment. Between 4 and 6 weeks after each treatment, serum samples were tested for the presence of HAMAs and tumor response was studied by imaging investigations.
Flow cytometric analysis
Lymphocyte subsets in the peripheral blood were quantified by flow cytometric analysis, including T cells (CD3, CD4 and CD8), NK cells (CD16/CD56), B cells (CD19) and lymphoma cells (CD5/CD19). Moreover, before Bi20 treatment, the expression levels of CD20 were Table 3 Summarized results of Bi20/DLI or SCT combination treatment B-cell depletion assays Bi20-mediated cytotoxicity was determined using a bioassay described earlier by Stanglmaier et al.
14 PBMCs (1 Â 10 6 per ml) obtained from the stem cell donor, as well as patient-derived cells (2 Â 10 5 per ml), were incubated with different concentrations of Bi20 (CD3 Â CD20), catumaxomab (CD3 Â EpCAM) (TRION Pharma, Munich, Germany) or rituximab (Roche, Basel, Switzerland). After 3 days, cells were collected and washed, and the percentage of viable CLL cells (CD5
by FACS analysis. The total number of viable cells was determined by trypan blue exclusion counting.
Results
Promising in vitro studies 14 encouraged us to treat patients with otherwise resistant B-lymphocyte malignancies that had relapsed after allo-SCT treatment. Three patients with refractory CLL and three patients with refractory HG-NHL were treated with escalating doses of Bi20 (CD3 Â CD20) followed by DLI or G-CSF-mobilized PBSCT. In two cases of CLL (patient nos. 2 and 3) and one case of aggressive NHL (patient no. 6), repeated courses of Bi20 and DLI were given without unexpected effects. Thereby, patient no. 6 received a total of 24 infusions with a cumulative dose of 13.610 mg of Bi20 and DLI from her HLA-haploidentical father. The overall survival ranged from 38 days (patient no. 5) to 486 days (patient no. 6). showed a dose-dependent decrease, followed by a short peak and drop phase after DLI. T-cell levels in patient no. 5 were below the detection limit (shown as baseline). Chemo: chemotherapy consisting of cytarabine, cisplatin and dexamethasone. DLI, donor lymphocyte infusion; HG-NHL, high-grade nonHodgkin's lymphoma; NK, natural killer. 
Response to treatment
In four of the six patients, we observed response to treatment. Two patients with HG-NHL (patient nos. 4 and 5) did not respond (Table 3 ). In patient no. 6, enlarged lymph nodes and B symptoms disappeared, and cough associated with a mediastinal tumor mass improved significantly for almost 4 months. In patients with CLL, a transient clinical (B symptoms, enlarged lymph nodes and Immunotherapy of NHL with Bi20 and DLI R Buhmann et al spleen) and hematological response was observed. Leukemia B cells in the peripheral blood disappeared with increasing doses of Bi20 (Figure 1a ), but reappeared within weeks after cessation of Bi20 despite DLI. Similarly, T cells (CD3/CD4; CD3/CD8) and NK cells (CD16/CD56) decreased dose-dependently during Bi20 treatment and recovered in part after DLI or SCT (Figures 1b and 2) . The CD4/CD8 ratio was unaffected and did not favor a shift toward a CD4 or CD8 sub-population (data not shown). Moreover, measurement of the cytokine profile revealed in cases of CLL and HG-NHL a transient but significant increase of IL-6, IL-8 and IL-10 at increasing concentrations of Bi20 accompanied by an increase of the C-reactive protein (Figures 3a,b and 4) . Interestingly, in the case of patient no. 6 (DLBCL), the release of IL-10 was observable only during the first treatment course, whereas it was not detectable during the second treatment course. For patient no. 5 (DLBCL), no cytokine release data are available regarding IL-8 and IL-10.
Experimental evaluation
Although all patients were stained positive for CD20, the expression level as expressed in MFI differed significantly.
To anticipate the cytotoxic capacity of Bi20, CLL cells of patient nos. 1 (MFI 20), 2 (MFI 120) and 3 (MFI 30) were incubated for 72 h with PBMCs of the corresponding stem cell donor in the presence of different concentrations of Bi20 (CD3 Â CD20), catumaxomab (CD3 Â EpCAM) and rituximab ( Figure 5) . In all cases, effective CLL depletion with Bi20 could be shown, in line with the clinical findings.
Adverse events Fever (CTCpgrade 3) and chills (CTCpgrade 2) were observed in all patients as treatment-related toxicities. Transient bone pain (CTCpgrade 3) was observed in patient no. 1 and a singular episode of hypotension (CTC grade 2) was observed in patient no. 3 (Table 3 ). In case of CLL, adverse effects appeared at Bi20 dose levels of 40-160 mg and in case of NHL not before dose levels 4200 mg, and were not more severe at higher concentrations. In general, adverse reactions could be controlled effectively by prolongation of the infusion time and decreased within hours after cessation of antibody application. In patient no. 6, a prolonged period (3 weeks) of leukopenia (CTC grade 4) was observed during the first treatment course after dose escalation of Bi20, up to 2000 mg, and SCT, which did not reappear in context with Bi20 application during the second treatment course. In CLL patient nos. 1, 2 and 3, application of Bi20 induced a transient decrease of granulocytes, which was most pronounced (CTCpgrade 4) in patient no. 2 (Table 3 ). In patient nos. 4 and 5, a slight increase of granulocytes was detected after Bi20 application. A temporary thrombocytopenia (CTCpgrade 3) (Table 3 ) occurred in all cases without requirement of transfusion. Moreover, laboratory abnormalities comprised a transient elevation of g-glutamyl transferase (GGT), not exceeding twofold of the upper limit of normal in patient nos. 1, 3, 4 and 6 (data not shown). The transaminases (alanine aminotransferase and aspartate aminotransferase), as well as bilirubin, were unaffected. In patient no. 2, after dose-escalated application of Bi20 (2 Â 1000 mg) and DLI (1 Â 10 8 CD3 þ cells per kg), a maximal but transient increase of GGT and bilirubin, up to eightfold, and fourfold of upper limit of normal, respectively, was observed. In patient no. 5, presenting with hepatic manifestation of lymphoma, a slight increase of GGT from sixfold up to eightfold of upper limit of normal was detected. No other organ toxicities (renal, cardiac and nervous system) were observed in any of the patients. HAMAs were not detectable, even after repeated applications of Bi20 (patient nos. 2, 3 and 6). Moreover, GVHD was not observed in any patient, although escalated applications of DLI and SCT were performed (patient nos. 2, 3 and 6).
Discussion
CD20 antibody treatment regimens have been proven to be highly effective in patients with B-cell NHL. 17 However, most patients ultimately relapse despite continued antibody treatment. 18 Mechanisms of resistance are not fully understood; some might be related to the tumor cells and some to host factors. Lymphoma cells may become resistant by decreased expression of CD20 antigen, or they may also activate antiapoptotic signal transduction pathways, which Immunotherapy of NHL with Bi20 and DLI R Buhmann et al renders these cells resistant to chemotherapy. 19, 20 Host factors involve effector cells of antibody-dependent cellular cytotoxicity and the reticulo-endothelial system removing antibody-loaded cells. 18 These functions may be defective;
variants of the FcgIII receptor have an impact on the response to rituximab treatment. 21 Bispecific antibodies could overcome the problem of resistance and insufficient stimulation of effector cells by PBMCs with different concentrations of Bi20 (CD3 Â CD20), catumaxomab (CD3 Â EpCAM) and rituximab (range: 0.5-250 ng/ml). After 72 h, CLL cell depletion (CD5 þ /CD19 þ ) was determined by FACS analysis and trypan blue exclusion. CD20 expression level is defined by MFI. The absolute CLL cell numbers in the assays without antibody (neg) were set as 100%. MFI, mean fluorescence intensity. directly binding with one arm to the tumor cell and the other arm to a T cell. An earlier study from our group showed effective stimulation of T cells with the secretion of tumor necrosis factor-a by CD20 Â CD3 and CD20 Â CD28 bispecific F(ab) 2 fragments.
22 CD20 Â CD28 induced reaction of allogeneic T cells directed against Blymphoma cells. However, in a patient with recurrent B-ALL after allo-SCT, responses to bispecific CD20 Â CD28 F(ab) 2 antibodies and DLIs were of short duration. T-cell immunity against ALL cells could not be shown. Therefore, we studied the effects of a complete bispecific antibody against CD20 Â CD3 (Bi20). This antibody has a functional Fc part and is therefore called 'trifunctional.' This new class of antibodies activates monocytes and DCs by binding to their Fc receptors and subsequent phagocytosis. 23 The additional property of activating accessory cells not only contributed to an effective cytotoxicity but it was also found to be a prerequisite for the induction of long-lasting antitumor immunity. 13 In a pilot trial, three patients with refractory, p53-mutated CLL and three patients with refractory HG-NHL (Burkitt-like lymphoma and DLBCL) were treated with the combination of the trifunctional antibody Bi20 and donor cellular transfusions. Thereby, in all patients suffering from CLL (patient nos. 1, 2 and 3), as well as in one patient with DLBCL (patient no. 6), we could observe a response to treatment. Two patients with HG-NHL (patient nos. 4 and 5) did not respond. In cases of response, we observed a significant improvement of clinical symptoms. Enlarged lymph nodes and spleen decreased in size and B symptoms disappeared almost completely. In patient no. 6, the respiratory symptoms (cough), caused by a large mediastinal tumor mass, improved markedly and remained asymptomatic for 4 months. In cases of CLL, a dosedependent decrease of leukemia cells in the peripheral blood could be observed. Unfortunately, responses were only transient and the disease relapsed in all cases.
The absence of antidrug antibodies (for example, HAMAs) allowed repeated treatment cycles. In two cases of CLL (patient nos. 2 and 3) and one case of HG-NHL (patient no. 6), repeated clinical and hematological responses could be observed. Thereby, the induction of HAMAs might be prevented by collateral targeting of CD20-bearing B cells, as the trifunctional antibodies catumaxomab (CD3 Â EpCAM) and ertumaxomab (CD3 Â HER2/neu) targeting tumor cells of epithelial origin did induce HAMAs. 24 Although we escalated the doses of donor cells, GVHD was observed neither in the HLA-identical nor in the haploidentical setting. This might go along with recently published data by Morecki et al. 25 in which, the presence of target cells, bispecific antibodies divert potentially tissue-damaging alloreactive cells from host tissues, susceptible to GVHD, to tumor cells. Moreover, escalated doses of Bi20 induced increased serum levels of IL-10, a Th1-antagonizing cytokine, which might additionally contribute to the prevention of the development of GVHD. 26, 27 Interestingly, a significant release of IL-10 was already observed in context with in vitro studies using the trifunctional antibodies catumaxomab (antiEpCAM Â anti-CD3), TRBs02/07 (anti-GD2/GD3 Â anti-CD3) and Bi20. 14, 28 However, so far, the therapeutic consequences are not well understood and need to be investigated further. Without any doubt, antibody concentrations in the range of micrograms (Table 3) caused a significant clinical and/or hematological response in patients previously refractory to treatment with alemtuzumab or rituximab. Thereby, even low expression levels of CD20 seemed to be sufficient for effective tumor cell depletion, although it might be assumed that higher expression levels probably correlate with a more favorable response pattern.
14 Strikingly, in the two cases of treatment failure, both patients had already presented before treatment initiation with low (patient no. 4) or even undetectable T-cell levels (patient no. 5), indicating that response to treatment might be strictly dependent on the presence of sufficient T cells during antibody application. Thus, although the induction of lymphopenia seems to be treatment associated using trifunctional antibodies, 29-31 a certain threshold of T cells seems to be absolutely necessary to mediate tumor-cell depletion. In general, the observed lymphopenic state resolved within 2-3 days after antibody application or could, at least in part, be replenished by DLI, as shown in the present trial, and should be anticipated in future clinical studies.
Treatment-related adverse effects were restricted to fever and chills and seemed to occur in high-grade lymphoma at higher dose ranges of Bi20 (4200 mg) than in CLL (dose range 40-160 mg). In our CLL patients, the circulating tumor load was very low, and a hypothesized correlation of adverse effects and tumor mass might also have to be assumed and anticipated in future clinical studies. In patient no. 1 presenting with bone pain, a subsequent analysis of bone marrow revealed a significantly reduced fraction of mutated (p53 deletion) lymphoma cells (data not shown). In general, adverse effects did not increase significantly at higher concentrations and could be controlled effectively by prolongation of the infusion time and supportive medication. The release of the inflammatory cytokine IL-6 followed the application of Bi20 and preceded the appearance of C-reactive protein at higher Bi20 concentrations. In all cases, the adverse effects disappeared after cessation of therapy.
A temporary thrombocytopenia (CTCpgrade 3) without requirement of transfusions was observed in all cases after Bi20 application. With the exception of the non-responders (patient nos. 4 and 5), granulocytopenia was observed in all other patients. In CLL, granulocytopenia resolved within days after Bi20 application. In patient no. 6 (DLBCL), a prolonged (3 weeks) granulocytopenia (CTC grade 4) was observed in the first treatment course, receiving the highest single dose of Bi20 (2000 mg) and the highest cumulative dose (6240 mg) per treatment course of all patients treated. After dose limitation up to 1000 mg per singular antibody application, during the second course, granulocytopenia, at least in the context of Bi20 application, did not reappear. A dose-dependent mechanism might therefore be assumed, although the precise mechanism is still unclear, and has to be considered in future clinical studies. Interestingly, in no case was any reactivation or infectious problem caused by CMV or EBV observed. Moreover, the hepatic toxicity profile appeared to be more favorable as compared with the other bispecific trifunctional antibodies, ertumaxomab (anti-CD3 Â anti-HER2/neu) or catumaxomab (anti-CD3 Â EpCAM), 24, 31, 32 even though our patients received higher singular as well as cumulative doses of Bi20. In only one case (patient no. 2), a significant Bi20/DLI-induced CTC grade 3 increase of GGT was observed in contrast to 8 of 17 (47%) cases with ertumaxomab and metastatic breast cancer. 31 The slight increase of GGT observed in patient no. 5 presenting with hepatic manifestation of lymphoma and non-responsiveness to therapy might at best be associated with disease progression rather than treatment induced.
Taken together, the combined treatment with Bi20 and adoptive cellular transfer could induce in part a prompt antitumor response in extensively pretreated, p53-mutated, and alemtuzumab and rituximab refractory patients, indicating its therapeutic potential. However, until now, the responses are of short duration and further studies are necessary to optimize the clinical outcome.
